Vironexis Biotherapeutics Inc.
Clinical trials sponsored by Vironexis Biotherapeutics Inc., explained in plain language.
-
Gene therapy breakthrough targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
Gene therapy breakthrough targets HER2 cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new gene therapy called VNX-202 for people with HER2-positive solid tumors. The study aims to see if the treatment is safe and can shrink tumors or slow cancer growth. It involves 27 adults whose cancer has not responded to standard treatments or wh…
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC